欧洲制药企业警告：竞争力不断衰落

欧洲九大制药公司主席周二致信包括Andy Burnham在内的欧洲各国领导人，敲响了欧洲医药产业竞争力下滑的警钟。1这些制药企业指出，美国和中国在过去两年内宣布了超过600亿美元的医药投资，而欧洲全球药物研发份额已从1990年的43%下跌至31%。1与此同时，欧洲临床试验份额从十年前的18%下降至9%，而中国的临床试验全球占比则从不足10%飙升至近30%。1

制药公司呼吁将药物视为战略基础设施，以期扭转局面。1数据显示，有49%的新批准疗法未在去年到达欧洲患者，这一比例高于2019年的46%。1欧洲新药平均批准时间为600天，但各国差异巨大，从德国的56天到罗马尼亚的1201天。1业界估计，如果缩小临床试验差距，欧洲可创造530亿欧元的价值和82000个就业机会。1

Nine leading European pharmaceutical companies have written to European leaders, including Andy Burnham, to sound an alarm about the continent's fading position in drug development and investment.1 The executives behind companies including AstraZeneca, GSK, Novo Nordisk, Boehringer Ingelheim, Chiesi, Sanofi, Ipsen, Novartis, and Roche argue that Europe is losing critical ground to competitors in the United States and China, citing a dramatic shift in global research capacity and regulatory speed.1

The companies point to striking disparities in investment and market dynamics over recent years. The United States and China have announced more than 600 billion dollars in pharmaceutical investments over the past two years, while Europe's share of global drug research and development has declined from 43 percent in 1990 to 31 percent today.1 The share of clinical trials conducted in Europe has fallen from 18 percent a decade ago to 9 percent currently, while China's proportion has surged from below 10 percent to nearly 30 percent.1 Additionally, 49 percent of newly approved therapies failed to reach European patients in the last year, an increase from 46 percent in 2019.1 Drug approval timelines across Europe remain inconsistent, ranging from 56 days in Germany to 1,201 days in Romania, with an average of 600 days.1

The pharmaceutical executives are calling on European governments to treat medicines as strategic infrastructure as part of a broader effort to restore competitiveness. Bridging the clinical trial gap alone could generate 53 billion euros in value and create 82,000 jobs for Europe, according to the companies' assessment.1 Europe maintains a pharmaceutical trade surplus exceeding 220 billion euros.1